Young, C B
Chen, T
Nusslock, R
Keller, J
Schatzberg, A F
Menon, V
Article History
Received: 5 August 2015
Revised: 27 March 2016
Accepted: 31 March 2016
First Online: 17 May 2016
Competing interests
: AFS has served as a consultant to Bay City Capital, BrainCells, CeNeRx, Cervel, Clintara, Depomed, Eli Lilly, Forum (EnVivo), Genentech, Gilead, Jazz, Lundbeck/Takeda, McKinsey, Merck, MSI, Naurex, Neuronetics, Novadel, One Carbon, Pfizer, PharmaNeuroBoost, Sunovion, Synosia and Xhale. AFS has had equity in Amnestix, CeNeRx, Corcept (co-founder), Forest Labs, Merck, Neurocrine, Pfizer, PharmaNeuroBoost, Synosia, Titan and Xhale. He is a named inventor on pharmacogenetic use patents on prediction of antidepressant response and glucocorticoid antagonists in psychiatry. The remaining authors declare no conflict of interest.